Cytokinetics
CYTK
148 hedge funds and large institutions have $513M invested in Cytokinetics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 6 closing their positions.
931% more call options, than puts
Call options by funds: $3.93M | Put options by funds: $381K
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
46% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 37
10% more funds holding
Funds holding: 134 → 148 (+14)
2% more capital invested
Capital invested by funds: $502M → $513M (+$11.3M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.48% less ownership
Funds ownership: 77.37% → 76.89% (-0.48%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.4M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.39M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.82M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$12.7M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$9.48M |
| 3 |
Renaissance Technologies
New York
|
-$3.74M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.14M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Walleye Capital
New York
| – | -$108K | -9,600 | Closed |
|
|
QT
152
Quantbot Technologies
New York
| – | -$7K | -700 | Closed |
|
|
GWS
153
Glassman Wealth Services
Vienna,
Virginia
| – | +$13 | +1 | New |
|
CYTK Hedge Fund Activity: Q3 2019 in Review
148 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2019, worth a combined $513M — up 2.2% from $502M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CYTK positions and 6 closed out — a net gain of 14 holders — while 54 added to existing stakes and 37 trimmed.
The largest buyer was Federated Hermes, adding an estimated $11.4M. The largest seller was BVF Inc, cutting an estimated $12.7M.
- 148 institutional investors held Cytokinetics (CYTK) as of Q3 2019, up from 134 in Q2 2019.
- Funds reported $513M of Cytokinetics stock for Q3 2019, up 2.2% quarter-over-quarter.
- 20 funds opened new Cytokinetics positions in Q3 2019 and 6 closed out, a net change of +14 holders.
- The largest Cytokinetics buyer in Q3 2019 was Federated Hermes, an estimated $11.4M added.
- The largest Cytokinetics seller in Q3 2019 was BVF Inc, an estimated $12.7M sold.
Based on aggregated 13F filings for Q3 2019.